

TITLE: Preparation of pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease
 INVENTOR(S): Bebbington, David; Binch, Hayley; Knegtel, Ronald; Golec, Julian M. C.; Patel, Sanjay; Charrier, Jean-Damien; Kay, David; Davies, Robert; Li, Pan; Wannamaker, Marion; Forster, Cornelia; Pierce, Albert
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 355 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002022606	A1	20020321	WO 2001-US28803	20010914 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, RU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2422378	A1	20020321	CA 2001-2422378	20010914 <--
AU 2001090944	A	20020326	AU 2001-90944	20010914 <--
US 20030055044	A1	20030320	US 2001-953505	20010914 <--
US 6638926	B2	20031028		
US 20030064981	A1	20030403	US 2001-952836	20010914 <--
US 6613776	B2	20030902		
US 20030064982	A1	20030403	US 2001-952875	20010914 <--
US 7473691	B2	20090106		
US 20030073687	A1	20030417	US 2001-952671	20010914 <--
US 6660731	B2	20031209		
US 20030078166	A1	20030424	US 2001-955601	20010914 <--
US 6696452	B2	20040224		
US 20030083327	A1	20030501	US 2001-952833	20010914 <--
US 6610677	B2	20030826		
EP 1317448	A1	20030611	EP 2001-971006	20010914 <--
EP 1317448	B1	20050504		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, MK, CY, AL, TR				
HU 2003002411	A2	20031128	HU 2003-2411	20010914 <--
ZA 2003001701	A	20040301	ZA 2003-1701	20010914 <--
ZA 2003001703	A	20040302	ZA 2003-1703	20010914 <--
JP 2004509116	T	20040325	JP 2002-526859	20010914 <--
JP 4105949	B2	20080625		
US 20040097501	A1	20040520	US 2001-953471	20010914 <--
US 7115739	B2	20061003		
US 20050004110	A1	20050106	US 2001-952878	20010914 <--
US 7098330	B2	20060829		
AT 294797	T	20050515	AT 2001-971006	20010914 <--
ES 2242771	T3	20051116	ES 2001-971006	20010914 <--
AT 326458	T	20060615	AT 2001-970969	20010914 <--
AT 327990	T	20060615	AT 2001-970971	20010914 <--
AT 327992	T	20060615	AT 2001-971082	20010914 <--
AT 327991	T	20060615	AT 2001-973050	20010914 <--

AT 326459	T	20060615	AT 2001-977779	20010914 <--
EP 1698627	A1	20060906	EP 2006-10798	20010914 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 346064	T	20061215	AT 2001-975210	20010914 <--
ES 2266258	T3	20070301	ES 2001-970971	20010914 <--
ES 2266259	T3	20070301	ES 2001-971082	20010914 <--
AT 363284	T	20070615	AT 2001-977783	20010914 <--
NZ 545284	A	20070629	NZ 1984-5452	20010914 <--
CN 100355750	C	20071219	CN 2001-817427	20010914 <--
CA 2432303	A1	20020829	CA 2001-2432303	20011219 <--
AU 2002255452	A1	20020904	AU 2002-255452	20011219 <--
AU 2002255452	B2	20060608		
CA 2432223	A1	20020906	CA 2001-2432223	20011219 <--
CA 2432223	C	20080520		
AU 2001297619	A1	20020912	AU 2001-297619	20011219 <--
AU 2001297619	B2	20060608		
EP 1345922	A1	20030924	EP 2001-271061	20011219 <--
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219 <--
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219 <--
JP 2004518743	T	20040624	JP 2002-565976	20011219 <--
JP 2004519479	T	20040702	JP 2002-567928	20011219 <--
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219 <--
NZ 526473	A	20050624	NZ 2001-526473	20011219 <--
EP 1702920	A1	20060920	EP 2006-11799	20011219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
ZA 2003001697	A	20040301	ZA 2003-1697	20030228 <--
ZA 2003001699	A	20040301	ZA 2003-1699	20030228 <--
ZA 2003001700	A	20040301	ZA 2003-1700	20030228 <--
ZA 2003001702	A	20040301	ZA 2003-1702	20030228 <--
ZA 2003001704	A	20040301	ZA 2003-1704	20030228 <--
ZA 2003001698	A	20040302	ZA 2003-1698	20030228 <--
IN 2003KN00293	A	20050311	IN 2003-KN293	20030310 <--
NO 2003001189	A	20030513	NO 2003-1189	20030314 <--
NO 326850	B1	20090302		
KR 876069	B1	20081226	KR 2003-703800	20030314 <--
MX 2003002293	A	20030606	MX 2003-2293	20030317 <--
ZA 2003004468	A	20040624	ZA 2003-4468	20030609 <--
ZA 2003004471	A	20040624	ZA 2003-4471	20030609 <--
ZA 2003004473	A	20040624	ZA 2003-4473	20030609 <--
ZA 2003004472	A	20040625	ZA 2003-4472	20030609 <--
ZA 2003004474	A	20040625	ZA 2003-4474	20030609 <--
NO 2003002704	A	20030821	NO 2003-2704	20030613 <--
MX 2003005609	A	20031006	MX 2003-5609	20030620 <--
MX 2003005610	A	20031006	MX 2003-5610	20030620 <--
US 20040224944	A1	20041111	US 2003-624800	20030722 <--
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023 <--
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125 <--
HK 1057890	A1	20051216	HK 2003-108726	20031128 <--
US 20040132781	A1	20040708	US 2003-736426	20031215 <--

US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210 <--
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315 <--
HK 1062565	A1	20090731	HK 2004-105510	20040727 <--
JP 2005097322	A	20050414	JP 2004-366925	20041217 <--
US 20070270444	A1	20071122	US 2006-369220	20060306 <--
AU 2006201228	A1	20060413	AU 2006-201228	20060321 <--
AU 2006201229	A1	20060413	AU 2006-201229	20060321 <--
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321 <--
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321 <--
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321 <--
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321 <--
AU 2006201265	A1	20060427	AU 2006-201265	20060321 <--
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725 <--
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723 <--
JP 2008115195	A	20080522	JP 2008-15681	20080125 <--
JP 2008189682	A	20080821	JP 2008-95581	20080401 <--
JP 2008260767	A	20081030	JP 2008-95584	20080401 <--
JP 2008222719	A	20080925	JP 2008-97620	20080403 <--
JP 2008189687	A	20080821	JP 2008-98506	20080404 <--
US 20080287444	A1	20081120	US 2008-109598	20080425 <--
JP 2008201808	A	20080904	JP 2008-121723	20080507 <--
JP 2008247920	A	20081016	JP 2008-121724	20080507 <--
JP 2008247921	A	20081016	JP 2008-121727	20080507 <--
AU 2008252044	A1	20090122	AU 2008-252044	20081203 <--
JP 2009155352	A	20090716	JP 2009-101481	20090417 <--
PRIORITY APPLN. INFO.:			US 2000-232795P	P 20000915 <--
			US 2000-257887P	P 20001221 <--
			US 2001-286949P	P 20010427 <--
			AU 2001-296871	A3 20010914 <--
			AU 2001-296875	A3 20010914 <--
			AU 2001-90914	A 20010914 <--
			AU 2001-90944	A3 20010914 <--
			AU 2001-91013	A3 20010914 <--
			AU 2001-94558	A3 20010914 <--
			AU 2001-96871	T0 20010914 <--
			AU 2001-96875	T0 20010914 <--
			EP 2001-971082	A3 20010914 <--
			JP 2002-526860	A3 20010914 <--
			US 2001-952671	A3 20010914 <--
			US 2001-953471	A3 20010914 <--
			US 2001-955601	A3 20010914 <--
			WO 2001-US28803	W 20010914 <--
			AU 2002-234047	A3 20011219 <--
			AU 2002-34047	T0 20011219 <--
			EP 2001-273861	A 20011219 <--
			EP 2001-994323	A3 20011219 <--
			JP 2002-551561	A3 20011219 <--
			JP 2002-557938	A3 20011219 <--
			JP 2002-559413	A3 20011219 <--
			JP 2002-563142	A3 20011219 <--
			JP 2002-565976	A3 20011219 <--
			JP 2002-567928	A3 20011219 <--
			US 2001-26966	A1 20011219 <--



WO 2001-US49139	W 20011219 <--
WO 2001-US50312	W 20011219 <--
JP 2002-551562	A3 20011220 <--
JP 2002-559414	A3 20011220 <--
US 2001-34019	A3 20011220 <--
US 2001-34683	A1 20011220 <--
IN 2003-KN795	A3 20030619 <--
US 2003-624800	A3 20030722 <--
US 2004-775699	A1 20040210 <--
JP 2004-366925	A3 20041217 <--
AU 2006-201396	A3 20060404 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:247582

ED Entered STN: 22 Mar 2002

GI



AB Title compds. I [wherein G = Ring C or Ring D; Ring C = (un)substituted Ph, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl; Ring D = (un)substituted monocyclic or bicyclic ring selected from aryl, heteraryl, heterocycl, or carbocycl; Z1 = N or CR9; Z2 = N or CH; Z3 = N or CRx; Z4 = N or CRy; Rx and Ry = independently TR3, or taken together with their intervening atoms form an (un)saturated fused ring having 1-3 ring heteroatoms; R2 and R2a = independently R, TWR6; or C2R2R2a = (un)substituted fused ring containing 0-3 heteroatoms; T = a bond or alkylidene chain; W = C(R6)2O, C(R6)2SO₂, C(R6)2NR6, CO, CO₂, CR6OCO, CR6OCNR6, C(R6)2NR6CO, C(R6)2NR6CO₂, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO₂NR6, C(R6)2NR6CONR6, or CONR6; R = H or (un)substituted aliphatic, (hetero)aryl, or heterocycl ring; R3 = R, halo, O, OR, COR, CO₂R, COCOR, COCH₂COR, NO₂, CN, SO₂-R, N(R4)2, CON(R4)2, SO₂N(R4)2, OCOR, NR4COR, NR4CO₂(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO₂N(R4)2, NR4SO₂R, or OCON(R4)2; R4 = R₇, COR₇, CO₂(aliphatic), CON(R7)₂, or SO₂R₇; or N(R4)2 = heterocycl or heteroaryl; R6 and R7 = independently H or (un)substituted aliphatic group; or N(R6)2 = heterocycl or heteraryl; or N(R7)2 = heterocycl or heteroaryl; R9 = R, halo, OR, COR, CO₂R, COCOR, etc.] were prepared as protein kinase inhibitors, especially as inhibitors of Aurora-2 and GSK-3, for treating diseases such as cancer, diabetes, and Alzheimer's disease. Claims cover (pyrimidinyl)pyrazolamines and indazolamines I [wherein Z1 and Z2 = N; Z3 = CRx; Z4 = CRy; G = Ring D]. Examples include data for approx. 300 invention compds. prepared by a variety of synthetic methods and bioassay results for the inhibition of GSK- β 3, Aurora-2, ERK, and Src. For instance, the N-(4-pyrimidinyl)-3-pyrazolamine II was prepared and exhibited Ki values of < 0.1 μ M for glycogen synthetase kinase 3 β (GSK-3 β) and 0.1-1.0 μ M for Aurora-2.

IC ICM C07D403-12
 ICS C07D401-14; A61K031-506; A61K031-4155; A61P035-00; C07D403-14;
 C07D405-14; C07D521-00; C07D493-04; C07D495-04; C07D471-04;
 C07D473-16
 CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1
 IT 607-68-1P, 2,4-Dichloroquinazoline 41339-17-7P,
 5-Nitro-1H-indazol-3-ylamine 61272-71-7P, 5-Bromo-1H-indazol-3-ylamine
 61272-72-8P, 5-Fluoro-1H-indazol-3-ylamine 404826-17-1P,
 2-(2-Trifluoromethylphenyl)pyrido[2,3-d][1,3]oxazin-4-one 404826-18-2P,
 2-(2-Trifluoromethylbenzoylamo)nicotinamide 404826-19-3P,
 4-Chloro-2-(3,5-dichlorophenyl)quinazoline 404826-26-2P,
 [4-(4-Methylpiperidin-1-yl)pyrimidin-2-yl](5-methyl-2H-pyrazol-3-yl)amine
 404827-60-7P, 7-Fluoro-1H-indazol-3-ylamine 404827-65-2P,
 5,7-Difluoro-1H-indazol-3-ylamine 404827-75-4P,
 6-Fluoro-1H-indazol-3-ylamine 404827-76-5P,
 7-Fluoro-6-trifluoromethyl-1H-indazol-3-ylamine 404827-77-6P,
 6-Bromo-1H-indazol-3-ylamine 404827-78-7P, 4-Fluoro-1H-indazol-3-ylamine
 404827-79-8P, 4-Pyrrol-1-yl-1H-indazol-3-ylamine 404827-80-1P,
 4-Chloro-5,6-dimethyl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-81-2P, 4-Chloro-2-(chlorophenyl)-5,6-dimethylpyrimidine
 404827-82-3P, 4-Chloro-6-methyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine 404827-85-6P,
 4-Chloro-2-(2,4-dichlorophenyl)-5,6-dimethylpyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
 404827-88-9P, 4-Chloro-6-pyridin-2-yl-2-(2-trifluoromethylphenyl)pyrimidine
 404827-89-0P,
 6-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidine 404827-90-3P, 7-Benzyl-4-chloro-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine 404827-91-4P,
 4-Chloro-2-(4-fluoro-2-trifluoromethylphenyl)quinazoline 404827-92-5P,
 4-Chloro-2-(2-chloro-5-trifluoromethylphenyl)quinazoline 404827-93-6P,
 4-Chloro-2-(2-chloro-4-nitrophenyl)quinazoline 404827-94-7P,
 4-Chloro-2-(2-trifluoromethylphenyl)quinazoline 404827-95-8P,
 4-Chloro-2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidine
 404827-96-9P, 4-Chloro-2-(2-chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidine 404827-97-0P,
 4-Chloro-2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapryrimidine 404827-98-1P,
 4-Chloro-8-methoxy-2-(2-trifluoromethylphenyl)quinazoline 404828-00-8P,
 2-(4-Chloroquinazolin-2-yl)benzonitrile 404828-01-9P,
 6-Methyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one
404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-pyrimidin-4-one 404828-03-1P, 2-(2-Chloro-5-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-04-2P,
 2-(4-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-05-3P,
 2-(4-Nitro-2-chlorophenyl)-3H-quinazolin-4-one 404828-06-4P,
 2-(5-Fluoro-2-trifluoromethylphenyl)-3H-quinazolin-4-one 404828-30-4P,
 (2-Chloroquinazolin-4-yl)(5-methyl-1H-pyrazol-3-yl)amine
404829-31-8P, (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404829-59-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of heterocyclic pyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-29-5P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](1H-indazol-3-yl)amine 404826-30-8P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl]amine 404826-31-9P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404826-32-0P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-33-1P,
[2-(2-Chlorophenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404826-34-2P,
(7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-35-3P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-36-4P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-37-5P,
(5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-38-6P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-39-7P,
[6-Benzyl-2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-40-0P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-41-1P,
(7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-42-2P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl]amine 404826-43-3P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl]amine 404826-44-4P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8-tetrahydroquinazolin-4-yl]amine 404826-46-6B,
(1H-Indazol-3-yl)(6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl)amine 404826-47-7P, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
(1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
(1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
[6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404826-51-3P,
[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404826-52-4P,
[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
(5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
[2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
[2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine 404826-60-4P, (5-Methyl-2H-pyrazol-3-yl)[2-(2-methylphenyl)quinazolin-4-

yl]amine 404826-61-5P, [2-(2,4-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-62-6P,
[2-(2,5-Dimethoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-63-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-64-8P, [2-(2-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-65-9P,
[2-(2,6-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-66-0P, [2-(2-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-67-1P, [2-(2,3-Dimethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404826-68-2P,
(5-Methyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-69-3P, [2-(2-Ethylphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-70-6P,
(2-Biphenyl-2-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404826-71-7P, [2-(2-Hydroxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-72-8P, [2-(2-Ethoxyphenyl)quinazolin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-73-9P,
[5-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-74-0P, [4-(Thiophen-2-yl)-2H-pyrazol-3-yl][2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-75-1P,
(4-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-76-2P, (5-tert-Butyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-77-3P,
(5-Phenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-78-4P, (4,5-Diphenyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-79-5P,
(4-Carbamoyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-80-8P, (2H-Pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-81-9P,
(5-Hydroxy-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-82-0P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-83-1P,
(5-Methoxymethyl-2H-pyrazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-84-2P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-85-3P,
(4-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-86-4P, (5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-87-5P,
(7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-88-6P, (5-Methyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-89-7P,
[2-(2,6-Dichlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-90-0P, [2-(2-Chlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-91-1P, (5-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-92-2P,
(4-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-93-3P, [2-(2,6-Dichlorophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404826-94-4P,
(1H-Indazol-3-yl)[2-(2-methylphenyl)quinazolin-4-yl]amine 404826-95-5P,
(7-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-96-6P, (6-Trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-98-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404826-99-9P, (4-Pyrrol-1-yl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-00-5P,
(5-Amino-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-01-6P, [2-(2-Chlorophenyl)quinazolin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-02-7P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404827-03-8P,
[2-(2-Chlorophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine

404827-04-9P, [2-(2-Chlorophenyl)quinazolin-4-yl](5-trifluoromethyl-1H-indazol-3-yl)amine 404827-05-0P,
[2-(2-Cyanophenyl)quinazolin-4-yl](1H-indazol-3-yl)amine 404827-07-2P,
(6-Chloro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-08-3P, (7-Fluoro-6-trifluoromethyl-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-09-4P,
(6-Bromo-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-10-7P, [2-(2,4-Bis-trifluoromethylphenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-11-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(4-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-12-9P,
[2-(2-Bromophenyl)quinazolin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-13-0P, (5,7-Difluoro-1H-indazol-3-yl)[2-(5-fluoro-2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-14-1P,
[2-(2,4-Dichlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-15-2P, [2-(2-Chloro-5-trifluoromethylphenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-16-3P,
(4-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-18-5P 404827-20-9P,
(5-Fluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-21-0P 404827-23-2P,
(5,7-Difluoro-1H-indazol-3-yl)[8-methoxy-2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine trifluoroacetate 404827-24-3P, [2-(2-Chloropyridin-3-yl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-26-5P,
[2-(4-Amino-2-chlorophenyl)quinazolin-4-yl](5,7-Difluoro-1H-indazol-3-yl)amine 404827-27-6P, (4,5,6,7-Tetrahydro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-28-7P,
(1H-Pyrazolo[4,3-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-29-8P, (1H-Pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-30-1P,
(6-Methyl-1H-pyrazolo[3,4-b]pyridin-3-yl)[2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
(5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
[6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404827-35-6P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404827-36-7P 404827-37-8P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-38-9P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)pyrido[2,3-d]pyrimidin-4-yl]amine 404827-40-3P,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-41-4P,
(5-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-42-5P,
[2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-43-6P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-44-7P,
(7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-45-8P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl]amine 404827-46-9P,
[2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](1H-indazol-3-yl)amine 404827-47-0P, [2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404827-48-1P,

[2-(2-Chlorophenyl)-6,7-dihydro-5H-cyclopentapyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine 404827-49-2P,
(1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-50-5P,
(7-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-51-6P,
(5,7-Difluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)-5,6,7,8,9,10-hexahydrocyclooctapyrimidin-4-yl]amine 404827-52-7P,
[6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404827-53-8P,
[6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404827-54-9P, (6-Fluoro-1H-indazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine 404827-55-0P,
3-[[2-(2-Trifluoromethylphenyl)quinazolin-4-yl]amino]-1H-indazole-5-carboxylic acid methyl ester 404827-56-1P,
(5-Methyl-1H-pyrazol-3-yl)[2-(2-naphthyl-1-yl)quinazolin-4-yl]amine 404827-58-3P, [2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-62-9P,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-64-1P,
[2-(2-Chlorophenyl)pyrido[2,3-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-67-4P,
[2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-70-9P,
[2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-72-1P,
[2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404827-74-3P,
[2-(2-Chlorophenyl)pyrido[3,4-d]pyrimidin-4-yl](5,7-difluoro-1H-indazol-3-yl)amine bis(trifluoroacetate) 404828-07-5P,
(1H-Indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-08-6P,
(5-Methyl-1H-pyrazol-3-yl)(2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404828-09-7P, (5-Methyl-2H-pyrazol-3-yl)(2-phenyl-6,7,8,9-tetrahydro-5H-cycloheptapyrimidin-4-yl)amine 404828-10-0P,
(5-Methyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)-amine 404828-11-1P, (7-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-12-2P, (6-Chloro-2-pyridin-4-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-13-3P,
(2-Cyclohexylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-14-4P, (5-Methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-15-5P, [2-(4-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-16-6P, [2-(4-Chlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-17-7P,
[2-(3,5-Dichlorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-18-8P, [2-(4-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-19-9P, [2-(3-*I*-Iodophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-20-2P,
[2-(4-Ethylsulfanylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-21-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-22-4P, [2-(4-*t*-Butylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-23-5P,
[2-(4-Chlorophenyl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine 404828-24-6P, (2-Benzo[1,3]dioxol-5-ylquinazolin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404828-25-7P, [2-(4-Dimethylaminophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-26-8P,
[2-(3-Methoxyphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-27-9P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dichlorophenyl)quinazolin-4-yl]amine 404828-28-0P,
[2-(3-Ethynylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-29-1P, [2-(3-Methylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-

yl)amine 404828-31-5P, [2-(3,5-Difluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-32-6P,
[2-(3-Chloro-4-fluorophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-34-8P, (5-Methyl-2H-pyrazol-3-yl)amine 404828-34-8P, [2-(3-Trifluoromethylphenyl)quinazolin-4-yl]amine 404828-35-9P,
[2-(3-Cyanophenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Isopropylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-36-0P, [2-(3-Ylquinazolin-4-yl)amine 404828-38-2P,
[2-(3-Acetylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-39-3P, [2-(3,5-Bis(trifluoromethyl)phenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-40-6P,
[2-(3-Hydroxymethylphenyl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-41-7P, (5-Methyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-42-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3-phenoxyphenyl)quinazolin-4-yl]amine 404828-43-9P 404828-44-0P,
(2-Phenylquinazolin-4-yl)(2H-pyrazol-3-yl)amine 404828-45-1P,
(2H-Pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-46-2P,
(5-Ethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-47-3P,
(2-Phenylquinazolin-4-yl)(5-propyl-2H-pyrazol-3-yl)amine 404828-48-4P,
(5-Isopropyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-49-5P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-50-8P, (5-tert-Butyl-2H-pyrazol-3-yl)(2-pyridin-4-ylquinazolin-4-yl)amine 404828-51-9P, (5-Cyclopentyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-52-0P,
(5-Phenyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-53-1P,
(5-Carboxy-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-55-3P,
(5-Hydroxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-56-4P, (5-Methoxymethyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-57-5P, [5-(3-Hydroxypyropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-59-7P,
[5-(3-Methoxypropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-60-0P, [5-(3-Aminopropyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-62-2P, (5-Isopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-63-3P,
(5-Allylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-64-4P, [5-(2-Methoxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-65-5P,
(5-Benzylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-66-6P, (5-Cyclohexylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-67-7P, (5-Diethylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-68-8P,
[5-(Benzylmethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-69-9P, (2-Phenylquinazolin-4-yl)(5-propylcarbamoyl-2H-pyrazol-3-yl)amine 404828-70-2P, [5-(Ethylisopropylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-71-3P,
(5-Cyclopropylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-72-4P, (5-Isobutylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-73-5P, [5-(3S)-3-Methoxymethylpyrrolidine-1-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-74-6P,
(2-Phenylquinazolin-4-yl)(5-m-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-75-7P, (2-Phenylquinazolin-4-yl)(5-p-tolylcarbamoyl-2H-pyrazol-3-yl)amine 404828-76-8P, (5-Methylcarbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-77-9P,
[5-(Morpholine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-78-0P, [5-(1-Methylpiperazine-4-carbonyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-79-1P,
[5-(2-Hydroxyethylcarbamoyl)-2H-pyrazol-3-yl](2-phenylquinazolin-4-yl)amine 404828-80-4P, (5-Carbamoyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-82-6P, (4-Bromo-2H-pyrazol-3-yl)(2-phenylquinazolin-4-

yl)amine 404828-83-7P, (4-Bromo-5-methyl-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-84-8P,
 (4-Cyano-2H-pyrazol-3-yl)(2-phenylquinazolin-4-yl)amine 404828-85-9P,
 (5-Methyl-2H-pyrazol-3-yl)(2-morpholin-4-ylquinazolin-4-yl)amine 404828-86-0P, (5-Methyl-2H-pyrazol-3-yl)(2-piperazin-1-ylquinazolin-4-yl)amine 404828-87-1P, [2-(4-Methylpiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-88-2P
 [2-(4-Methylpiperazin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-89-3P, (5-Methyl-2H-pyrazol-3-yl)(2-piperidin-1-ylquinazolin-4-yl)amine 404828-90-6P, [2-(Azepan-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-91-7P,
 [2-[4-(2-Hydroxyethyl)piperidin-1-yl]quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-92-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404828-94-0P,
 [2-(1,4-Dioxa-8-azaspiro[4.5]dec-8-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-95-1P, [2-(4-Cyclopentylaminopiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-96-2P,
 [2-(4-Hydroxypiperidin-1-yl)quinazolin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404828-97-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxy-4-phenylpiperidin-1-yl)quinazolin-4-yl]amine 404828-98-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(1,3-dihydroisoindol-2-yl)quinazolin-4-yl]amine 404828-99-5P, [2-(Azepan-1-yl)quinazolin-4-yl](5-cyclopropyl-2H-pyrazol-3-yl)amine 404829-00-1P,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-1H-isoquinolin-2-yl)quinazolin-4-yl]amine 404829-01-2P,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(2,3-dihydroindol-1-yl)quinazolin-4-yl]amine 404829-02-3P, (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-hydroxymethylpiperidin-1-yl)quinazolin-4-yl]amine 404829-03-4P,
 (5-Cyclopropyl-2H-pyrazol-3-yl)[2-(3,4-dihydro-2H-quinolin-1-yl)quinazolin-4-yl]amine 404829-05-6P, 5-(Piperidine-1-carbonyl)-2H-pyrazol-3-yl-[2-(piperidine-1-yl)quinazolin-4-yl]amine 404829-06-7P,
 (5-Hydroxymethyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-07-8P, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(piperidin-1-yl)quinazolin-4-yl]amine 404829-08-9P, (5-Carbamoyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)quinazolin-4-yl]amine 404829-09-0P,
 (5,7-Difluoro-1H-indazol-3-yl)(2-phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)amine 404829-10-3P, (2-Phenyl-5,6,7,8-tetrahydroquinazolin-4-yl)(5-trifluoromethyl-1H-indazol-3-yl)amine 404829-11-4P,
 (7-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-12-5P, (5-Fluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-13-6P,
 (5,7-Difluoro-1H-indazol-3-yl)(2-phenylquinazolin-4-yl)amine 404829-14-7P, (1H-Indazol-3-yl)[2-(3-trifluoromethylphenyl)quinazolin-4-yl]amine 404829-15-8P, (2-Phenylquinazolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine 404829-16-9P,
 [5-(3-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-17-0P,
 (6-Oxo-5-phenyl-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl)-(2-phenylquinazolin-4-yl)amine 404829-18-1P,
 [5-(4-Methoxyphenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-19-2P,
 [5-(2,4-Dichlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-21-6P,
 [6-Oxo-5-(3-trifluoromethylphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine
 RL: **PAC** (**Pharmacological activity**); SPN (**Synthetic preparation**);
 THU (**Therapeutic use**); BIOL (**Biological study**); PREP (**Preparation**); USES (**Uses**)
 (protein kinase inhibitor; preparation of heterocyclypyrazolamines and analogs as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

IT 404829-22-7P, [6-Oxo-5-(4-Phenoxyphenyl)-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-23-8P,
[5-(4-Chlorophenyl)-6-oxo-5,6-dihydro-1H-pyrazolo[4,3-c]pyridazin-3-yl](2-phenylquinazolin-4-yl)amine 404829-24-9P,
(2-Imidazol-1-ylquinazolin-4-yl)(1H-indazol-3-yl)amine 404829-25-0P,
(1H-Indazol-3-yl)(2-(2-methylimidazol-1-yl)quinazolin-4-yl)amine 404829-26-1P, (1H-Indazol-3-yl)(2-piperidin-1-ylquinazolin-4-yl)amine
404829-27-2P, (1H-Indazol-3-yl)[2-(octahydroquinolin-1-yl)quinazolin-4-yl]amine 404829-28-3P, (1H-Indazol-3-yl)[2-(2,6-dimethylmorpholin-4-
yl)quinazolin-4-yl]amine 404829-29-4P,
(5-Methyl-2H-pyrazol-3-yl)(2-phenylpyrimidin-4-yl)amine
404829-30-7P, [6-(4-Acetamidophenylsulfanyl)-2-phenylpyrimidin-4-
yl](5-methyl-2H-pyrazol-3-yl)amine 404829-32-9P,
[2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404829-33-0P, [2-(4-Methylpiperidin-1-yl)-5-nitropyrimidin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404829-34-1P,
[5-Amino-2-(4-Methylpiperidin-1-yl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-
yl)amine 404829-35-2P, [5-Amino-6-methyl-2-(4-methylpiperidin-1-
yl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P
, [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl](5-phenyl-2H-pyrazol-3-
yl)amine 404829-37-4P,
[2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl](5-furan-2-yl-2H-pyrazol-3-
yl)amine 404829-38-5P,
[5-(Furan-2-yl)-2H-pyrazol-3-yl](6-methyl-2-phenylpyrimidin-4-yl)amine
404829-39-6P 404829-40-9P,
(5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(4-
trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-41-0P,
[2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-methylpyrimidin-4-yl](5-furan-2-yl-
2H-pyrazol-3-yl)amine 404829-42-1P,
[2-(2,3-Dihydrobenzo[1,4]dioxin-2-yl)-6-ethylpyrimidin-4-yl](5-methyl-2H-
pyrazol-3-yl)amine 404829-43-2P,
(6-Ethyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404829-44-3P, [6-Methyl-2-phenylpyrimidin-4-yl](5-phenyl-2H-
pyrazol-3-yl)amine 404829-45-4P,
[6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-
yl)amine 404829-46-5P,
(5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(4-methylphenyl)-pyrimidin-4-
yl]amine 404829-47-6P,
(6-Methoxyethyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-
pyrazol-3-yl)amine 404829-49-8P,
(6-Methyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl](5-methyl-
2H-pyrazol-3-yl)amine 404829-51-2P,
[2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine
404829-52-3P, (5-Methyl-1H-pyrazol-3-yl)(6-methyl-2-p-
tolylpyrimidin-4-yl)amine 404829-53-4P,
(1H-Indazol-3-yl)(6-methoxyethyl-2-phenylpyrimidin-4-yl)amine
404829-54-5P, (5-Methyl-2H-pyrazol-3-yl)-(2-pyrindin-4-ylthieno[3,2-
d]pyrimidin-4-yl)amine 404829-55-6P,
(5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[3,4-d]pyrimidin-4-yl)amine
404829-56-7P, (5-Methyl-2H-pyrazol-3-yl)-(2-phenylpyrido[2,3-d]pyrimidin-4-
yl)amine 404829-57-8P, (5-Cyclopropyl-2H-pyrazol-3-yl)-(2-
phenylpyrido[3,4-d]pyrimidin-4-yl)amine 404829-60-3P,
(5-Cyclopropyl-2H-pyrazol-3-yl)[2-(4-methylpiperidin-1-yl)pyrrolo[3,2-
d]pyrimidin-4-yl]amine 404829-62-5P,
(5-Fluoro-1H-indazol-3-yl)-(2-phenyl-5,6,7,8-tetrahydropyrido[4,3-
d]pyrimidin-4-yl)amine 404829-63-6P,
(1H-Indazol-3-yl){3-(2-trifluoromethylphenyl)isoquinoline-1-yl}amine
404829-65-8P, (5,7-Difluoro-1H-indazol-3-yl){3-(2-

trifluoromethylphenyl)isoquinolin-1-yl]amine 404829-66-9P,
 (1H-Indazol-3-yl)(2-phenylquinolin-4-yl)amine 404829-67-0P,
 (2-Phenylquinolin-4-yl)(1H-pyrazolo[4,3-b]pyridin-3-yl)amine
 404829-68-1P, (1H-Indazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-4-
 yl]amine 404829-69-2P, (5,7-Difluoro-1H-indazol-3-yl)[2-(2-
 trifluoromethylphenyl)quinolin-4-yl]amine 404829-70-5P,
 [2-(2-Trifluoromethylphenyl)quinolin-4-yl](1H-pyrazolo[4,3-b]pyridin-3-
 yl)amine 404829-71-6P, (2-Phenylquinazolin-4-yl)(2H-1,2,4-triazol-3-
 yl)amine 404829-72-7P, (5-Methyl-2H-1,2,4-triazol-3-yl)(2-
 phenylquinazolin-4-yl)amine 404829-73-8P,
 (2H-1,2,4-Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinazolin-4-yl]amine
 404829-74-9P, (5-Methyl-2H-1,2,4-triazol-3-yl)[2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404829-75-0P,
 (5-Methylsulfanyl-2H-1,2,4-triazol-3-yl)[2-(2-
 trifluoromethylphenyl)quinazolin-4-yl]amine 404829-76-1P,
 (1H-[1,2,4]Triazol-3-yl)[3-(2-trifluoromethylphenyl)isoquinolin-1-yl]amine
 404829-77-2P, (2-Phenylquinolin-4-yl)(1H-1,2,4-triazol-3-yl)amine
 404829-78-3P, (1H-[1,2,4]Triazol-3-yl)[2-(2-trifluoromethylphenyl)quinolin-
 4-yl]amine 404829-79-4P,
 (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl]-2-(2-
 trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-80-7P 404829-81-8P
404829-82-9P 404829-83-0P 404845-75-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation);
 USES (Uses)

(protein kinase inhibitor; preparation of heterocyclylpyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer,
 diabetes, and Alzheimer's disease)

IT 404827-83-4P, 4-Chloro-6-cyclohexyl-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-84-5P,
 4-Chloro-6-phenyl-2-(2-trifluoromethylphenyl)pyrimidine
404827-86-7P, 4-Chloro-6-(2-chlorophenyl)-2-(2-
 trifluoromethylphenyl)pyrimidine 404827-87-8P,
 4-Chloro-6-(2-fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidine
404828-02-0P, 6-Cyclohexyl-2-(2-trifluoromethylphenyl)-3H-
 pyrimidin-4-one 404829-31-8P,
 (6-Chloro-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; preparation of heterocyclylpyrazolamines and analogs as
 protein kinase inhibitors for treatment of cancer, diabetes,
 and Alzheimer's disease)


RN 404827-83-4 HCPLUS

CN Pyrimidine, 4-chloro-6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA
 INDEX NAME)




RN 404827-84-5 HCPLUS


CN Pyrimidine, 4-chloro-6-phenyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX
 NAME)




RN 404827-86-7 HCAPLUS
CN Pyrimidine, 4-chloro-6-(2-chlorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)




RN 404827-87-8 HCAPLUS
CN Pyrimidine, 4-chloro-6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-
(CA INDEX NAME)



RN 404828-02-0 HCAPLUS
CN 4(3H)-Pyrimidinone, 6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]- (CA INDEX
NAME)



RN 404829-31-8 HCAPLUS
CN 4-Pyrimidinamine, 6-chloro-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA
INDEX NAME)




IT 404826-28-4P, [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-Methyl-2H-pyrazol-3-yl)amine 404826-46-6P,
 (1H-Indazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-47-7P, (1H-Indazol-3-yl)[6-phenyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-48-8P,
 (1H-Indazol-3-yl)[6-(pyridin-4-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-49-9P,
 (1H-Indazol-3-yl)[6-(pyridin-2-yl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-50-2P,
 [6-(2-Chlorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404826-51-3P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404826-52-4P,
 [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-53-5P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine 404826-54-6P, [5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404826-55-7P,
 (5,7-Difluoro-1H-indazol-3-yl)[5,6-Dimethyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404826-56-8P,
 (2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl)(5,7-difluoro-1H-indazol-3-yl)amine 404826-57-9P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](7-fluoro-1H-indazol-3-yl)amine 404826-58-0P,
 [2-(2-Chlorophenyl)-5,6-dimethylpyrimidin-4-yl](5-fluoro-1H-indazol-3-yl)amine 404826-59-1P,
 [2-(2,4-Dichlorophenyl)-5,6-dimethylpyrimidin-4-yl](1H-indazol-3-yl)amine 404827-32-3P, [6-Methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-phenyl-2H-pyrazol-3-yl)amine 404827-33-4P,
 (5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl]amine 404827-34-5P,
 [6-Ethyl-2-(2-trifluoromethoxyphenyl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404827-35-7P,
 [6-Cyclohexyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404827-53-8P,
 [6-(2-Fluorophenyl)-2-(2-trifluoromethylphenyl)pyrimidin-4-yl](1H-indazol-3-yl)amine 404829-29-4B,
 (5-Methyl-2H-pyrazol-3-yl)(2-phenylpyrimidin-4-yl)amine 404829-30-7P, [6-(4-Acetamidophenoysulfanyl)-2-phenylpyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404829-36-3P,
 [6-Methyl-2-(4-methylphenyl)pyrimidin-4-yl](5-phenyl-2H-pyrazol-3-yl)amine 404829-37-4P, [2-(4-Chlorophenyl)-6-methylpyrimidin-4-yl](5-furan-2-yl-2H-pyrazol-3-yl)amine 404829-38-5P,
 [5-(Furan-2-yl)-2H-pyrazol-3-yl](6-methyl-2-phenylpyrimidin-4-yl)amine 404829-39-6P, 404829-40-9P,
 (5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-43-2P,
 (6-Ethyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404829-44-3P, (6-Methyl-2-phenylpyrimidin-4-yl)(5-phenyl-2H-

pyrazol-3-yl)amine 404829-45-4P,
 [6-Ethyl-2-(4-trifluoromethylphenyl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404829-46-5P,
 (5-Furan-2-yl-2H-pyrazol-3-yl)[6-methyl-2-(4-methylphenyl)-pyrimidin-4-yl]amine 404829-47-6P,
 (6-Methoxymethyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404829-48-7P, (5,6-Dimethyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404829-49-8P,
 (6-Methyl-2-phenylpyrimidin-4-yl)(5-methyl-2H-pyrazol-3-yl)amine 404829-50-1P, [6-Ethyl-2-(4-methylphenyl)pyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404829-51-2P,
 [2-(4-Chlorophenyl)-6-ethylpyrimidin-4-yl](5-methyl-2H-pyrazol-3-yl)amine 404829-52-3P, (5-Methyl-1H-pyrazol-3-yl)(6-methyl-2-p-tolylpyrimidin-4-yl)amine 404829-53-4P,
 (1H-Indazol-3-yl)(6-methoxymethyl-2-phenylpyrimidin-4-yl)amine 404829-79-4P, (1H-Indazol-3-yl)[5-methyl-6-morpholin-4-yl]-2-(2-trifluoromethylphenyl)pyrimidin-4-yl]amine 404829-82-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation);
 THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (protein kinase inhibitor; preparation of heterocyclypyrazolamines and
 analogs as protein kinase inhibitors for treatment of cancer,
 diabetes, and Alzheimer's disease)


RN 404826-28-4 HCPLUS

CN 4-Pyrimidinamine, 2-(2-chlorophenyl)-5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404826-46-6 HCPLUS

CN 1H-Indazol-3-amine, N-[6-methyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-47-7 HCPLUS

CN 1H-Indazol-3-amine, N-[6-phenyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-48-8 HCPLUS

CN 1H-Indazol-3-amine, N-[6-(4-pyridinyl)-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-49-9 HCPLUS

CN 1H-Indazol-3-amine, N-[6-(2-pyridinyl)-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 404826-50-2 HCPLUS


CN 1H-Indazol-3-amine, N-[6-(2-chlorophenyl)-2-(2-(trifluoromethyl)phenyl)-4-pyrimidinyl]- (CA INDEX NAME)



RN 404826-51-3 HCPLUS


CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-(2-(trifluoromethyl)phenyl)-4-

pyrimidinyl]- (CA INDEX NAME)




RN 404826-52-4 HCPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-53-5 HCPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]- (CA INDEX NAME)




RN 404826-54-6 HCPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)




RN 404826-55-7 HCPLUS

CN 1H-Indazol-3-amine, N-[5,6-dimethyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-56-8 HCPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5,7-difluoro- (CA INDEX NAME)




RN 404826-57-9 HCPLUS

CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-7-fluoro- (CA INDEX NAME)



RN 404826-58-0 HCPLUS


CN 1H-Indazol-3-amine, N-[2-(2-chlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-5-fluoro- (CA INDEX NAME)



RN 404826-59-1 HCPLUS


CN 1H-Indazol-3-amine, N-[2-(2,4-dichlorophenyl)-5,6-dimethyl-4-pyrimidinyl]-

(CA INDEX NAME)




RN 404827-32-3 HCPLUS

CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-33-4 HCPLUS

CN 4-Pyrimidinamine, N-(5-(2-furanyl)-1H-pyrazol-3-yl)-6-methyl-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-34-5 HCPLUS


CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 404827-52-7 HCPLUS
CN 1H-Indazol-3-amine, N-[6-cyclohexyl-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404827-53-8 HCPLUS
CN 1H-Indazol-3-amine, N-[6-(2-fluorophenyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)




RN 404829-29-4 HCPLUS
CN 4-Pyrimidinamine, N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-30-7 HCPLUS
CN Acetamide, N-[4-[(6-[(5-methyl-1H-pyrazol-3-yl)amino]-2-phenyl-4-pyrimidinyl]thio)phenyl]- (CA INDEX NAME)




RN 404829-36-3 HCPLUS
CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-phenyl-1H-pyrazol-3-yl)-
(CA INDEX NAME)




RN 404829-37-4 HCPLUS
CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-
methyl- (CA INDEX NAME)




RN 404829-38-5 HCPLUS
CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-phenyl-
(CA INDEX NAME)




RN 404829-39-6 HCPLUS
CN 4-Pyrimidinamine, 6-methyl-N-(5-phenyl-1H-pyrazol-3-yl)-2-[4-
(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-40-9 HCPLUS
 CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 404829-43-2 HCPLUS
 CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-44-3 HCPLUS
 CN 4-Pyrimidinamine, 6-methyl-2-phenyl-N-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-45-4 HCPLUS
 CN 4-Pyrimidinamine, 6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-[4-

(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 404829-46-5 HCPLUS

CN 4-Pyrimidinamine, N-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-2-(4-methylphenyl)- (CA INDEX NAME)




RN 404829-47-6 HCPLUS

CN 4-Pyrimidinamine, 6-(methoxymethyl)-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-48-7 HCPLUS


CN 4-Pyrimidinamine, 5,6-dimethyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-49-8 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-N-(5-methyl-1H-pyrazol-3-yl)-2-phenyl- (CA INDEX NAME)




RN 404829-50-1 HCAPLUS
CN 4-Pyrimidinamine, 6-ethyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-51-2 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-6-ethyl-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 404829-52-3 HCAPLUS
CN 4-Pyrimidinamine, 6-methyl-2-(4-methylphenyl)-N-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 404829-53-4 HCAPLUS
CN 1H-Indazol-3-amine, N-[6-(methoxymethyl)-2-phenyl-4-pyrimidinyl]- (CA INDEX NAME)



RN 404829-79-4 HCAPLUS
CN 1H-Indazol-3-amine, N-[5-methyl-6-(4-morpholinyl)-2-[2-(trifluoromethyl)phenyl]-4-pyrimidinyl]- (CA INDEX NAME)



RN 404829-82-9 HCAPLUS
CN 4-Pyrimidinamine, 2-(4-chlorophenyl)-N-(5-methyl-1H-pyrazol-3-yl)-6-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)